These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21370008)

  • 21. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
    Skaland I; Ă˜vestad I; Janssen EA; Klos J; Kjellevold KH; Helliesen T; Baak JP
    J Clin Pathol; 2008 Jan; 61(1):68-71. PubMed ID: 17412872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.
    van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE
    PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
    Francz M; Egervari K; Kardos L; Toth J; Nemes Z; Szanto J; Szollosi Z
    J Clin Pathol; 2010 Apr; 63(4):341-6. PubMed ID: 19965795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of two HER-2 FISH kits on formalin-fixed paraffin-embedded tissues: signal detection and simple procedure].
    Uhara M; Matsuda K; Shimojyo Y; Hidaka E; Kumagai T; Uehara T; Sano K; Honda T
    Rinsho Byori; 2010 Jan; 58(1):25-9. PubMed ID: 20169940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH).
    Hwang HC; Gown AM
    Methods Mol Biol; 2016; 1406():61-70. PubMed ID: 26820945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer.
    Nishimura R; Kagawa A; Tamogami S; Kojima K; Satou M; Yamashita N; Teramoto N; Aogi K
    Breast Cancer; 2016 Mar; 23(2):211-5. PubMed ID: 25033760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
    Rhodes A; Jasani B; Couturier J; McKinley MJ; Morgan JM; Dodson AR; Navabi H; Miller KD; Balaton AJ
    Am J Clin Pathol; 2002 Jan; 117(1):81-9. PubMed ID: 11789735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
    Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
    Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
    Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixation time does not affect expression of HER2/neu.
    Goldsmith JD; Allred DC; Beasley MB; Eisen R; Fulton RS; Gown AM; Hammond ME
    Am J Clin Pathol; 2011 Mar; 135(3):484; author reply 485. PubMed ID: 21350107
    [No Abstract]   [Full Text] [Related]  

  • 40. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.